{
  "symbol": "GKOS",
  "company": "Glaukos Corporation",
  "generated_at": "2026-06-24T07:36:48.217Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-24T01:08:48.556Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.",
      "trigger": "[insider_cluster_universe] 7 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-24T01:08:48.534Z",
      "skip": true,
      "reason": "Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.",
      "score": 14,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 8,
        "mispricing": 0,
        "quality": 0,
        "technical": 6
      },
      "debug_path": "drafts/2026-06-24-GKOS.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-24T01:08:18.255Z",
      "summary": "The investigation trigger was a cluster of 30 Form 4 filings in 14 days, but upon detailed reading all were routine director RSU grants (vested at $0) from the May 28 annual meeting — zero open-market purchases confirmed. Two notable selling events exist: CEO/CFO Navratil executed Rule 10b5-1 sales of ~$200K on April 10 and a final tranche of ~$201K on June 16, while COO Gilliam sold $2.8M on May 1 near the 52-week high ($143.54). The stock is within 9% of its all-time high, has run +34% YTD, and trades at an extreme forward P/E of 303x with negative FCF — a classic fully-valued mega-cap growth/medtech profile where IV elevation (50-60%) makes income strategies the only structure worth pursuing. No material mispricing was identified; no edge in data.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 29,
      "walltime_min": 27,
      "debug_path": "dossiers/2026-06-24-GKOS.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "GKOS",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (38.8%)",
      "rsi_neutral": "0 (60.4)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (9d ago)",
      "from_high": "0 (-6.5%)"
    },
    "summary": "BUY (score +7) · 12-1 mom 38.8% · RSI 60.4 · above_both · -6.5% from high",
    "last_close": 134.65,
    "one_month_ago_close": 139.03,
    "twelve_month_ago_close": 100.2,
    "twelve_one_momentum_pct": 38.75,
    "rsi_14": 60.4,
    "ma_stack": "above_both",
    "from_period_high_pct": -6.5,
    "period_high": 144.01,
    "price_targets": {
      "bear": 100.81,
      "fair": 139.55,
      "bull": 170,
      "bear_return_pct": -25.1,
      "fair_return_pct": 3.6,
      "bull_return_pct": 26.3,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 138,
        "target_mean": 157.5,
        "target_high": 170,
        "analyst_count": 12
      }
    },
    "generated_at": "2026-06-24T07:36:48.215Z"
  }
}